End point title: Number of Subjects With Sustained Reduction in Disability (SRD) Assessed by EDSS (After Alemtuzumab Treatment) at Year 2 of the Extension Study

| Statistical analysis title | Switch CAMMS323/03409 (Post Alemtuzumab) |
| :--- | :--- |
| Statistical analysis <br> description | The percentage and 95\% CI of the subjects with SAD were <br> estimated by the Kaplan Meier method. |
| Comparison groups | IFNB1a/Alemtuzumab Switch CAMMS323/03409 (Post <br> Alemtuzumab) |
| Number of subjects <br> included in analysis | 65 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| Method | Percentage with SRD |
| Parameter type | 16.92 |
| Point estimate | $95 \%$ |
| Confidence interval | 2 -sided |
| level | 9.75 |
| sides | 28.47 |
| lower limit | Switch CAMMS324/03409 (Post Alemtuzumab) |
| upper limit | The percentage and 95\% CI of the subjects with SAD were <br> estimated by the Kaplan Meier method. |
| Statistical analysis title |  |
| Statistical analysis <br> description | IFNB1a/Alemtuzumab Switch CAMMS324/03409 (Post <br> Alemtuzumab) |
| Comparison groups | 102 |
| Number of subjects <br> included in analysis | Pre-specified |
| Analysis specification | superiority |
| Analysis type | Percentage with SRD |
| Method | 13.89 |
| Parameter type | $25 \%$ |
| Point estimate | 22.33 |
| Confidence interval | level | | sides |
| :--- |
| lower limit |
| upper limit |

